Mourhaf Traboulssi, MD
Cardiovascular Disease · Sandusky, OHNPI 1639158827
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,636 of the $1,999 with a category attached, or 81.8%. 18 manufacturers reported payments, led by Abbott at 26.2% of the total.
Across 65 payments — averaging $30.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$525
- Astellas Pharma US Inc$384
- Novartis$213
- Heartflow, Inc.$140
- Johnson & Johnson$133
- Medtronic$122
- plus $483 from 12 others
Across 24 payments — averaging $13,569 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$315K
- Merck$11K
What the payments were for
- Food & beverage$1,63682%
- Education$36318%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 5 | $525 |
| Astellas Pharma US Inc | 5 | $384 |
| Novartis | 12 | $213 |
| Heartflow, Inc. | 1 | $140 |
| Johnson & Johnson | 9 | $133 |
| Medtronic | 1 | $122 |
| AstraZeneca | 7 | $103 |
| Amgen | 6 | $96 |
| Boehringer Ingelheim | 3 | $60 |
| E.r. Squibb & Sons, L.L.C. | 4 | $54 |
| Sanofi-aventis U.S. LLC | 3 | $43 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $30 |
| Pfizer | 2 | $23 |
| Lantheus Medical Imaging, Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
| Aegerion Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip$294
- AMPLATZER AMULET$143
- FFRct$140
- CoreValve Evolut$122
How this compares
$1,999 in reported general payments places this provider in the 55th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 884 | $1,080,378 |
| XareltoRivaroxaban | 315 | $423,441 |
| EntrestoSacubitril/Valsartan | 51 | $86,848 |
| JardianceEmpagliflozin | 53 | $70,126 |
| BrilintaTicagrelor | 32 | $34,839 |
| Dofetilide | 108 | $19,358 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 58 | $14,164 |
| Metoprolol Succinate | 978 | $13,927 |
| Atorvastatin Calcium | 1,053 | $13,209 |
| Rosuvastatin Calcium | 631 | $12,321 |
| NexletolBempedoic Acid | 20 | $10,979 |
| Flecainide Acetate | 191 | $8,896 |
| Valsartan | 197 | $6,960 |
| Amiodarone Hcl | 254 | $6,765 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 216 | $6,034 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $23 | $1,080,378884 claims |
| Johnson & JohnsonXarelto | $133 | $423,441315 claims |
| NovartisEntresto | $213 | $86,84851 claims |
| Boehringer IngelheimJardiance | $60 | $70,12653 claims |
| AstraZenecaBrilinta | $103 | $34,83932 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 827 cardiovascular disease providers in Ohio.
Other cardiovascular disease in Sandusky
- Hassan IbrahimSandusky$140K
- Guilherme AttizzaniCleveland$1.3M
- Gregory LamCircleville$428K
- Emil HayekHudson$379K
- Abraham LincoffCleveland$369K
- Oussama WazniCleveland$367K
- Ian NeelandCleveland$329K
- Kamal ShemisaCincinnati$314K
- Mehdi ShishehborElyria$237K
- Abdu HawwaGarfield Hts$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.